New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States.
Level 4 - case-series / case-control
Cross-sectional survey of a panel sample
What was done
A 2025 survey was administered to a nationally representative sample of U.S. adults via the RAND American Life Panel to measure self-reported prevalence rates of GLP-1 agonist use and associated side effects.
What was found
The abstract reports no numerical data, prevalence percentages, sample size, or specific side effect frequencies. It notes contextually that prescriptions for GLP-1 agonists have more than tripled since 2020.
Why it matters
It offers population-level descriptive data on the real-world uptake and side-effect profile of GLP-1 agonists following their rapid expansion in clinical use.
Limits
The abstract provides no quantitative results or sample size. The findings rely on self-reported survey data from a panel, which is subject to recall and reporting biases without clinical verification.
Cited by
- supports Estimates indicate that roughly one in seven Americans have tried a GLP-1 receptor agonist drug.